Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Goetz

Showing results (151-160 of 397) with videos related to

Pageof 40
Sort By:
Breast Cancer Research and Treatment|January 1, 2018
Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancerTufia C Haddad, Antonino D'Assoro, Vera Suman, et al.
Molecular Cancer Research : MCR|February 25, 2021
Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant ModelsCalley J Jones, Malayannan Subramaniam, Michael J Emch, et al.
Human Pathology|September 19, 2009
Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancerSejal S Shah, Rhett P Ketterling, Matthew P Goetz, et al.
AJR. American Journal of Roentgenology|July 26, 2011
Palliation of painful metastatic disease involving bone with imaging-guided treatment: comparison of patients' immediate response to radiofrequency ablation and cryoablationPaul G Thacker, Matthew R Callstrom, Timothy B Curry, et al.
Breast Cancer Research and Treatment|May 24, 2019
Metaplastic breast cancer has a poor response to neoadjuvant systemic therapyZahraa Al-Hilli, Grace Choong, Michael G Keeney, et al.
The Journal of Chemical Physics|December 17, 2015
Vibrational properties of organic donor-acceptor molecular crystals: Anthracene-pyromellitic-dianhydride (PMDA) as a case studyA Fonari, N S Corbin, D Vermeulen, et al.
Annals of Surgical Oncology|November 1, 2017
Using Size and Grade to Identify Women Aged ≥ 70 Years with Endocrine-Responsive Breast Cancer at Low Risk of Nodal Positivity : Letter to Editor Reply to "Sized influences nodal status in women aged ≥ 70 with endocrine responsive breast cancer" by Fitzal, Florian et al. in Ann Surg Oncol DOI 10.1245/s10434-017-6156-0Judy C Boughey, Tanya L Hoskin, Jessemae L Welsh, et al.
Breast Cancer Research : BCR|April 5, 2019
The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1Junmei Cairns, James N Ingle, Krishna R Kalari, et al.
Clinical Breast Cancer|January 18, 2016
Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer PatientsWinston W Tan, Jacob B Allred, Alvaro Moreno-Aspitia, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2021
Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer careEmanuele Garreffa, Ahmed Hamad, Ciara C O'Sullivan, et al.
Pageof 40

Showing results (151-160 of 397) with videos related to

Sort By:
Pageof 40
Breast Cancer Research and Treatment|January 1, 2018
Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancerTufia C Haddad, Antonino D'Assoro, Vera Suman, et al.
Molecular Cancer Research : MCR|February 25, 2021
Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant ModelsCalley J Jones, Malayannan Subramaniam, Michael J Emch, et al.
Human Pathology|September 19, 2009
Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancerSejal S Shah, Rhett P Ketterling, Matthew P Goetz, et al.
AJR. American Journal of Roentgenology|July 26, 2011
Palliation of painful metastatic disease involving bone with imaging-guided treatment: comparison of patients' immediate response to radiofrequency ablation and cryoablationPaul G Thacker, Matthew R Callstrom, Timothy B Curry, et al.
Breast Cancer Research and Treatment|May 24, 2019
Metaplastic breast cancer has a poor response to neoadjuvant systemic therapyZahraa Al-Hilli, Grace Choong, Michael G Keeney, et al.
The Journal of Chemical Physics|December 17, 2015
Vibrational properties of organic donor-acceptor molecular crystals: Anthracene-pyromellitic-dianhydride (PMDA) as a case studyA Fonari, N S Corbin, D Vermeulen, et al.
Annals of Surgical Oncology|November 1, 2017
Using Size and Grade to Identify Women Aged ≥ 70 Years with Endocrine-Responsive Breast Cancer at Low Risk of Nodal Positivity : Letter to Editor Reply to "Sized influences nodal status in women aged ≥ 70 with endocrine responsive breast cancer" by Fitzal, Florian et al. in Ann Surg Oncol DOI 10.1245/s10434-017-6156-0Judy C Boughey, Tanya L Hoskin, Jessemae L Welsh, et al.
Breast Cancer Research : BCR|April 5, 2019
The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1Junmei Cairns, James N Ingle, Krishna R Kalari, et al.
Clinical Breast Cancer|January 18, 2016
Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer PatientsWinston W Tan, Jacob B Allred, Alvaro Moreno-Aspitia, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2021
Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer careEmanuele Garreffa, Ahmed Hamad, Ciara C O'Sullivan, et al.
Pageof 40